Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

s in patients within the first 12 days following initiation of treatment but also significantly reduced persistent diarrhea, disease recurrence or death through day 40 of the study."

The analysis was independently funded by the NIHR Biomedical Research Centre, Oxford, a research partnership between the Oxford Radcliffe Hospitals and the University of Oxford.

Study Methods

The analysis was performed using data from two prospective, randomized, double-blinded, non-inferiority Phase 3 studies evaluating DIFICID and oral vancomycin in the treatment of CDAD in adults 18 years of age or older. A non-inferiority design was utilized to demonstrate the efficacy of DIFICID (200 mg orally twice daily for 10 days) compared to vancomycin (125 mg orally four times daily for 10 days) in adults with CDAD. The studies enrolled a total of 1,164 adults with confirmed CDAD. The primary objective of both studies was to show that a 10-day course of DIFICID was as effective as oral vancomycin in achieving a clinical cure at the end of therapy. Clinical cure was defined as resolution of diarrhea (no more than 3 unformed stools for 2 consecutive days) maintained for the duration of therapy with no further requirement for therapy assessed two days after the end of the 10 day treatment. Subjects meeting the criteria for clinical cure were followed for 28 days after the end of treatment (36-40 days after randomization) and assessed for the additional efficacy endpoints of recurrence and global cure. Recurrence was defined by the reappearance of more than 3 unformed stools in any 24-hour period with C. difficile toxin A or B or both detected and a need for retreatment.  Global cure was defined as clinical cure without recurrence.  

To compile the results, researchers conducted a post-hoc exploratory analysis to determine the time-to-event for a composite endpoint of persistent diarrhea, disease recurrence or death of the combined intent-to-tre
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 1, 2014 The global high content ... by the ,Threat of Obsolescence, wherein technologies as well ... Pharmaceutical and biotechnology companies as well as academic and ... screening as a powerful research tool in drug discovery. ... segment in the high content screening market. In high ...
(Date:10/1/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop and produce enzymes and other ... industrial enzymes industries, today announced the receipt of ... commercial scale production of Abengoa,s proprietary cellulase enzymes, ... Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 2014 Trovagene, Inc., (NASDAQ:  TROV) a ... Eli Diamond , MD, Assistant Attending Neurologist ... clinical data from an ongoing study demonstrating the ... the determination of oncogene mutational status in cell-free ... were presented to both treating physicians and patients ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... 19, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... leading manufacturer of medical dressings, medical disposables and non-woven ... announced today that the Company will participate in Arab ... 27th, at the International Convention Exhibition Centre in Dubai, ...
... LAKE CITY, Jan. 18, 2011 TechniScan ... device company engaged in the development and commercialization of ... that it has signed a Product Development Agreement with ... $1.5 million. TechniScan and Womens3D will ...
Cached Medicine Technology:Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 2Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 3TechniScan Signs Agreement With Texas-Based Company to Co-Develop A New Version of Its Breast Imaging Device 2TechniScan Signs Agreement With Texas-Based Company to Co-Develop A New Version of Its Breast Imaging Device 3
(Date:10/2/2014)... October 02, 2014 USARAD Holdings ... and telemedicine solutions provider including its SecondOpinions.com® division, ... have joined its Executive Team as President & ... Brent Backhaus, USARAD’s new President and COO, is ... of progressively responsible experience in commercial-, medical- and ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 Robins ... from the Associated Builders and Contractors (ABC) of ... at tonight’s banquet held at Sheraton Birmingham Hotel., ... Massachusetts, Healthcare $10 Million to $25 Million, Obelisk ... Dental Clinic, Federal Government $10 Million to $25 ...
(Date:10/2/2014)... Maureen Salamon HealthDay Reporter ... women with a neurotic personality style and prolonged stress ... new research suggests. Tracking 800 women over nearly ... most anxious, jealous and moody -- which they defined ... the risk of developing Alzheimer,s compared to women scoring ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... reduced by breast-feeding. Nor will delaying the introduction of a ... help prevent celiac disease. Those are the conclusions ... New England Journal of Medicine . The new ... celiac disease if mothers breast-feed their babies and introduce gluten ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2
... , TUESDAY, Jan. 4 (HealthDay News) -- Nearly 60 ... victims of violence, abuse or crime in the past year. ... happened. Researchers led by David Finkelhor of the University ... parents of children up to 9 years old in 2008. More ...
... Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Common ... stem cell defect, a finding that could potentially lead ... study reveals. Researchers say they discovered that a ... stem cells turn into hair-producing progenitor cells. That defect, ...
... , TUESDAY, Jan. 4 (HealthDay News) -- The ... (arrhythmias) that can cause sudden death may be underestimated, ... healthy people without heart disease found detectable changes in ... to polluted air. The findings suggest that air ...
... Jan. 4 (HealthDay News) -- Levels of schooling may affect ... heart attack called acute ST-segment elevation myocardial infarction (STEMI), a ... of heart attack, STEMI occurs when the coronary artery is ... heart. In the new study, Dr. Rajendra H. ...
... Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Simply measuring ... how many years they have left. In fact, a ... older people,s future life span about as well as taking ... disease. Walking speed may not be a perfect window ...
... YORK (Jan. 4, 2011) Researchers have produced a lasting anti-cocaine ... bits of the common cold virus with a particle that mimics ... published Jan. 4 in the online edition of Molecular Therapy ... researchers say this novel strategy might be the first to offer ...
Cached Medicine News:Health News:Survey Finds Much Victimization of Children Goes Unreported 2Health News:Stem Cell Defect Might Help Spur Common Baldness 2Health News:Stem Cell Defect Might Help Spur Common Baldness 3Health News:Higher Education May Benefit Some Heart Attack Patients 2Health News:Fast Walkers May Have More Years Ahead of Them 2Health News:Fast Walkers May Have More Years Ahead of Them 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3
... a broad selection of tip ... wide variety of ophthalmic procedures. ... packaged sterile, complete with a ... in the "off " position ...
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
Medicine Products: